The risk-based breast screening (RIBBS) study protocol: a personalized screening model for young women
La radiologia medica · 2024
DOI: 10.1007/s11547-024-01797-9 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift La radiologia medica, 2024. Verfasst von Gisella Gennaro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Veneto Institute of Oncology (IOV) IRCCS, Padua, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammography, Early Detection of Cancer, Breast Density. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regione del Veneto.
Abstract (Originalsprache)
The optimal mammography screening strategy for women aged 45–49 years is a matter of debate. We present the RIBBS study protocol, a quasi-experimental, prospective, population-based study comparing a risk- and breast density-stratified screening model (interventional cohort) with annual digital mammography (DM) screening (observational control cohort) in a real-world setting. The interventional cohort consists of 10,269 women aged 45 years enrolled between 2020 and 2021 from two provinces of the Veneto Region (northen Italy). At baseline, participants underwent two-view digital breast tomosynthesis (DBT) and completed the Tyrer-Cuzick risk prediction model. Volumetric breast density (VBD) was calculated from DBT and the lifetime risk (LTR) was estimated by including VBD among the risk factors. Based on VBD and LTR, women were classified into five subgroups with specific screening protocols for subsequent screening rounds: (1) LTR ≤ 17% and nondense breast: biennial DBT; (2) LTR ≤ 17% and dense breast: biennial DBT and ultrasound; (3) LTR 17–30% or LTR > 30% without family history of BC, and nondense breast: annual DBT; (4) LTR 17–30% or > 30% without family history of BC, and dense breast: annual DBT and ultrasound; and (5) LTR > 30% and family history of BC: annual DBT and breast MRI. The interventional cohort is still ongoing. An observational, nonequivalent control cohort of 43,000 women aged 45 years participating in an annual DM screening programme was recruited in three provinces of the neighbouring Emilia-Romagna Region. Cumulative incidence rates of advanced BC at three, five, and ten years between the two cohorts will be compared, adjusting for the incidence difference at baseline. Trial registration This study is registered on Clinicaltrials.gov (NCT05675085).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Veneto Institute of Oncology (IOV) IRCCS, Padua, Italy.
- Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy. lauro.bucchi@irst.emr.it.
- Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy.
- SER - Servizio Epidemiologico Regionale e Registri, Azienda Zero, Padua, Italy.
- Cancer Prevention Unit, Local Health Authority, Forlì, Italy.
- Direzione Prevenzione, Sicurezza Alimentare, Veterinaria, Regione del Veneto, Venice, Italy.
Förderung
- Regione del Veneto
Zitieren
APA
Gennaro, G., Bucchi, L., Ravaioli, A., Zorzi, M., Falcini, F., Russo, F., & Caumo, F. (2024). The risk-based breast screening (RIBBS) study protocol: a personalized screening model for young women. La radiologia medica. https://doi.org/10.1007/s11547-024-01797-9
Vancouver
Gennaro G, Bucchi L, Ravaioli A, Zorzi M, Falcini F, Russo F, et al. The risk-based breast screening (RIBBS) study protocol: a personalized screening model for young women. La radiologia medica. 2024. doi:10.1007/s11547-024-01797-9
BibTeX
@article{Gennaro2024,
author = {Gennaro, Gisella and Bucchi, Lauro and Ravaioli, Alessandra and Zorzi, Manuel and Falcini, Fabio and Russo, Francesca and Caumo, Francesca},
title = {The risk-based breast screening (RIBBS) study protocol: a personalized screening model for young women},
journal = {La radiologia medica},
year = {2024},
doi = {10.1007/s11547-024-01797-9}
}
EUVIMED